1
|
Franco-Arroyo NN, Viveros-Paredes JM, Zepeda-Morales ASM, Roldán E, Márquez-Aguirre AL, Zepeda-Nuño JS, Velázquez-Juárez G, Fafutis-Morris M, López-Roa RI. β-Caryophyllene, a Dietary Cannabinoid, Protects Against Metabolic and Immune Dysregulation in a Diet-Induced Obesity Mouse Model. J Med Food 2022; 25:993-1002. [PMID: 35792574 DOI: 10.1089/jmf.2021.0166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Obesity is an abnormal or excessive accumulation of fat in the body that exacerbates metabolic and inflammatory processes, and impairs the health of afflicted individuals. β-caryophyllene is a natural sesquiterpene that is a dietary cannabinoid with anti-inflammatory properties and potential activity against metabolic diseases. In the present study, we evaluated the effect of β-caryophyllene on C57BL/6 mice using a diet-induced obesity model. Male mice were randomly assigned to the following groups over a 16-week period: (1) standard diet as lean control, (2) high-fat diet (HFD) as obese control, and (3) HFD + β-caryophyllene with β-caryophyllene at 50 mg/kg. Treatment with β-caryophyllene improved various metabolic parameters including increased total body weight, fasting glucose levels, oral-glucose tolerance, insulin tolerance, fasting triglycerides, adipocyte hypertrophy, and liver macrovesicular steatosis. β-caryophyllene also modulated the levels and expression of immune response factors including adiponectin, leptin, insulin, interleukin-6, tumor necrosis factor-a, and Toll-like receptor-4. Our data indicate that chronic supplementation with β-caryophyllene can improve relevant metabolic and immunological processes in obese mice. This protocol was approved by the Institutional Committee for Care and Use of Laboratory Animals from the University of Guadalajara with protocol code CUCEI/CINV/CICUAL-01/2022.
Collapse
Affiliation(s)
- Noel N Franco-Arroyo
- Department of Pharmacobiology; Pharmaceutical Research and Development Laboratory, CUCEI, University of Guadalajara, Mexico
| | - Juan M Viveros-Paredes
- Department of Pharmacobiology; Pharmaceutical Research and Development Laboratory, CUCEI, University of Guadalajara, Mexico
| | - A Sara M Zepeda-Morales
- Department of Pharmacobiology, Clinical Analysis Laboratory, CUCEI, University of Guadalajara, Mexico
| | - Erika Roldán
- Department of Mathematics Geometry & Technical Visualization, University of Munich, Germany.,Department for Topology and Neuroscience, Federal Polytechnic School of Lausanne, Switzerland
| | - Ana L Márquez-Aguirre
- Pharmaceutical and Medical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, Mexico
| | - José S Zepeda-Nuño
- Department of Microbiology and Pathology, Pathology Research and Diagnosis Center, CUCS, University of Guadalajara, Mexico
| | | | - Mary Fafutis-Morris
- Department of Physiology, Immunology and Dermatology Research Center, CUCS, University of Guadalajara, Mexico
| | - Rocio I López-Roa
- Department of Pharmacobiology; Pharmaceutical Research and Development Laboratory, CUCEI, University of Guadalajara, Mexico
| |
Collapse
|
2
|
Peña-Rodríguez M, Vega-Magaña N, García-Benavides L, Zepeda-Nuño JS, Gutierrez-Silerio GY, González-Hernández LA, Andrade-Villanueva JF, Del Toro-Arreola S, Pereira-Suárez AL, Bueno-Topete MR. Butyrate administration strengthens the intestinal epithelium and improves intestinal dysbiosis in a cholestasis fibrosis model. J Appl Microbiol 2021; 132:571-583. [PMID: 33982373 DOI: 10.1111/jam.15135] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Revised: 04/17/2021] [Accepted: 05/09/2021] [Indexed: 01/11/2023]
Abstract
AIM Intestinal dysfunction in cirrhosis patients is linked to death by bacterial infections. Currently, there is no effective therapy for this complication. This study aims to evaluate butyrate, a novel postbiotic, on the intestinal inflammatory response, tight junction proteins and the microbiota in the cholestasis model. METHODS AND RESULTS Wistar rats underwent 15 days of bile duct ligation (BDL). We administered butyrate at a concentration of 1%. The BDL group did not receive treatment. The results showed that butyrate could significantly reduce pro-inflammatory cytokines (IL-17A, IFN-γ, TNF-α) in the ileum and colon while promoting IL-10 expression in the colon. Moreover, it significantly promotes tight junction protein (cld-1, occludin and ZO-1) expression in the ileum. A similar effect was observed in the colon except for ZO-1. Additionally, butyrate limited taxa diversity loss and promoted probiotic genera expansion such as Lachnospira, Prevotella and Lactobacillus. The increase in Turicibacter and Clostridiaceae distinguished the BDL group. CONCLUSIONS Butyrate is effective in regulating the inflammatory response, tight junction proteins and limits bacterial diversity loss. SIGNIFICANCE AND IMPACT OF THE STUDY This research reveals that butyrate could represent an interesting postbiotic metabolomic intervention for intestinal epithelium dysfunction in liver disease.
Collapse
Affiliation(s)
- M Peña-Rodríguez
- Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México
| | - N Vega-Magaña
- Instituto de Investigación en Ciencias Biomédicas, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México
| | - Leonel García-Benavides
- Laboratorio de Patología, Departamento de Microbiología y Patología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México
| | - J S Zepeda-Nuño
- Departamento de Ciencias Biomédicas, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá, Jalisco, México
| | - G Y Gutierrez-Silerio
- Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México
| | - L A González-Hernández
- Unidad de VIH, Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, México
| | - J F Andrade-Villanueva
- Unidad de VIH, Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, México
| | - S Del Toro-Arreola
- Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México
| | - A L Pereira-Suárez
- Instituto de Investigación en Ciencias Biomédicas, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México.,Departamento de Microbiología y Patología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México
| | - M R Bueno-Topete
- Departamento de Biología Molecular y Genómica, Instituto de Investigación en Enfermedades Crónico Degenerativas, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México
| |
Collapse
|